Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes

<br><strong>PURPOSE<br></strong> Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Sco...

Full description

Bibliographic Details
Main Authors:	Garcia-Manero, G, Santini, V, Almeida, A, Platzbecker, U, Jonasova, A, Silverman, LR, Falantes, J, Reda, G, Buccisano, F, Fenaux, P, Buckstein, R, Diez Campelo, M, Larsen, S, Valcarcel, D, Vyas, P, Giai, V, Olíva, EN, Shortt, J, Niederwieser, D, Mittelman, M, Fianchi, L, La Torre, I, Zhong, J, Laille, E, Lopes de Menezes, D, Skikne, B, Beach, CL, Giagounidis, A
Format:	Journal article
Language:	English
Published:	American Society of Clinical Oncology 2021

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes

Similar Items